Core Insights - The training program for the delegation focused on enhancing expertise in microwave ablation (MWA) techniques, featuring both theoretical discussions and hands-on demonstrations [1][2] - Baird Medical emphasizes its commitment to global knowledge-sharing and medical innovation, aiming to advance MWA technology and improve patient care worldwide [3] - Baird Medical is a publicly traded company on NASDAQ, specializing in minimally invasive MWA technology for various medical conditions [4] Training Program Details - The first day of the program included theoretical discussions and hands-on demonstrations at Baird Medical's facility, providing a deeper understanding of MWA applications [1] - On the second day, the delegation observed live MWA procedures at Sun Yat-sen University Cancer Center and engaged in discussions with leading specialists [2] - The program concluded with an in-depth session on thyroid microwave ablation techniques, enhancing the participants' knowledge of the latest advancements in MWA technology [2] Company Overview - Baird Medical is a leader in providing advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer through MWA technology [4] - The company is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices [4]

Core Insights - The article highlights a two-day training course on microwave ablation (MWA) techniques led by Dr. Jennifer Kuo, aimed at enhancing procedural safety and clinical applications for physicians from the U.S. and Mexico [1][4]. Group 1: Training Program - The training included hands-on sessions where participants, such as Dr. Hesham, practiced simulated procedures to improve their skills in thyroid MWA, focusing on device operation and ablation precision [2]. - A live case observation session allowed physicians to gain insights into MWA's preoperative planning, intraoperative techniques, and postoperative management, with positive feedback on the practical nature of the training [3]. Group 2: Company Overview - Baird Medical is a leading provider of minimally invasive MWA technology, addressing conditions like thyroid nodules, breast disease, uterine fibroids, and liver cancer, and is publicly traded on NASDAQ [5]. - The company is committed to accelerating the adoption of innovative treatments through specialized training and aims to enhance procedural expertise among physicians globally [4].

Core Insights - Baird Medical showcased its minimally invasive microwave ablation (MWA) technology at NASIT 2025, generating significant interest and discussions among clinicians regarding future thyroid therapies [1][3] - Dr. Emad Kandil presented compelling case studies highlighting MWA as a safe and effective alternative to traditional thyroid surgery, emphasizing benefits such as reduced procedure times and improved patient outcomes [2] - The company aims to enhance treatment options through further research and strategic partnerships, reinforcing its commitment to innovation in patient care [3][4] Company Overview - Baird Medical is a leading provider of minimally invasive MWA technology, focusing on advanced treatment solutions for conditions like thyroid nodules, breast disease, uterine fibroids, and liver cancer [4] - The company is publicly traded on NASDAQ and is dedicated to improving patient care through precision, efficiency, and safety in its medical devices [4]

Core Insights - The 2025 Microcap Conference served as a significant platform for Baird Medical to showcase its technological advancements and explore strategic opportunities in the industry [1][2][4] Company Highlights - Baird Medical presented its minimally invasive microwave ablation technology, emphasizing its leadership in research and development [2][4] - The company shared its global expansion strategy following the recent FDA 510(k) clearance for the U.S. market, indicating readiness for market penetration [2][3] Strategic Initiatives - Baird Medical's leadership engaged in one-on-one meetings with investors to discuss growth plans, market penetration strategies, and product promotion initiatives in the U.S. [3] - Extensive discussions were held regarding potential mergers and acquisitions, focusing on resource integration, technological synergies, and market collaboration [3][4] Future Outlook - The company aims to leverage insights and partnerships from the conference to enhance global market expansion and improve patient outcomes through innovative technologies [4] - Baird Medical plans to continue investing in research and development to enhance product quality and performance while actively exploring merger and acquisition opportunities [4] Company Background - Baird Medical is a leading provider of minimally invasive microwave ablation technology, addressing conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer [5] - The company is publicly traded on NASDAQ and is committed to enhancing patient care through precision, efficiency, and safety in its medical devices [5]

On October 2, 2024 (U.S. Eastern Time), Baird Medical successfully listed on the Nasdaq Stock Market, marking a significant milestone in its international growth strategy. This listing reinforces the Company's commitment to innovation, global market expansion, and enhancing shareholder value as it continues to pioneer cutting-edge medical solutions. PatentsIn 2024, Baird Medical further expanded its intellectual property portfolio, securing patents that enhance MWA technology and production efficiency: Inve ...

The NASIT Conference is a premier forum for education, research, and collaboration in thyroid interventions, and Baird Medical is honored to participate in this key industry event. The Company's invitation highlights its growing prominence in the field of microwave ablation while offering a valuable opportunity to engage with global experts, industry leaders, and potential partners. As a returning participant, Baird Medical is excited to contribute to discussions on the latest advancements in MWA technology ...

NEW YORK, Jan. 23, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation technology (MWA), announced today that it will participate in the highly anticipated Microcap Conference, set to take place at the Borgata Hotel in Atlantic City, New Jersey, from January 28 to January 30, 2025. Baird Medical specializes in the design and development of cutting-edge needles and apparatus for microwave ablation of thyroid nodules. Th ...

Core Insights - Baird Medical is expanding its presence into San Francisco as part of its U.S. growth strategy, following its participation in the J.P. Morgan Health Conference [1] - The company has received FDA 510(k) clearance for its Microwave Ablation (MWA) technology, which has been successfully used to treat hundreds of patients, demonstrating significant recovery and positive outcomes [3] - Collaboration with medical specialists and comprehensive training initiatives are being implemented to enhance physician education and awareness of MWA technology [4] Company Overview - Baird Medical is a leader in minimally invasive microwave ablation technology, providing advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer [5] - The company is publicly traded on NASDAQ under the ticker BDMD and is focused on improving patient care through innovative medical devices [5] Market Recognition - Dr. Terrence K. Trapp, an otolaryngologist, has integrated Baird Medical's MWA system into his practice, indicating a growing interest in minimally invasive treatments for thyroid nodules [2] - Dr. Emad Kandil from Tulane University has performed over 100 MWA procedures, highlighting the clinical potential and increasing recognition of Baird Medical's innovations within the medical community [3]

Following its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes. "Being in San Francisco during the J.P. Morgan Healthcare Conference provided a valuable opportunity to engage with shareholders, innovators, and advisors in the healthcare sector," said Haimei Wu, Ch ...

Led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, the session welcomed participation from Dr. Sean P. Nikravan, MD, FACE, an endocrinologist based in Newport Beach, CA, and Dr. Erin H. Lin, DO, a specialist in Surgical Oncology and General Surgery from the University of California, Irvine. Both physicians had the opportunity to observe seven live MWA procedures, refine advanced techniques, and evaluate the unique capabilities of this groundbreaking t ...